Format

Send to:

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2014 May;58(5):2934-7. doi: 10.1128/AAC.02572-13. Epub 2014 Feb 18.

Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Author information

  • 1Optimer Pharmaceuticals, Inc., San Diego, California, USA.

Abstract

Fidaxomicin (FDX) is a narrow-spectrum antibiotic for the treatment of Clostridium difficile-associated diarrhea. While FDX and rifamycins share the same target (RNA polymerase), FDX exhibits a unique mode of action distinct from that of rifamycins. In comparative microbiological studies with C. difficile, FDX interacted synergistically with rifamycins, demonstrated a lower propensity for the development of resistance to rifamycins, and exhibited no cross-resistance with rifamycins. These results highlight differences in the mechanisms of action of FDX and rifamycins.

PMID:
24550338
[PubMed - in process]
PMCID:
PMC3993244
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk